Study of adjuvant treatment of alendronate sodium in human chondrosarcoma cells

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2014, Vol. 19 ›› Issue (4): 410-414.

Previous Articles Next Articles

Study of adjuvant treatment of alendronate sodium in human chondrosarcoma cells

LE Fang-hua¹, LOU Xing-fa¹, FANG Qin-hua²

¹Department of Pharmacy, Hangzhou Xiaoshan District Hospital of TCM, Hangzhou 311201, Zhejiang, China;
²Department of Orthopaedics, Hangzhou Xiaoshan District Hospital of TCM, Hangzhou 311201, Zhejiang, China

Received:2013-07-30 Revised:2014-03-11 Online:2014-04-26 Published:2020-07-24

Abstract

Abstract: AIM: To observe the effect of alendronate sodium (fosamax) on inhibition of invasion and migration of human chondrosarcoma cells. METHODS: Human chondrosarcoma cells were treated with 100 μmol/L of alendronate sodium. Matrix metalloproteinase (MMP-2) activity and invasion ability were observed by gelatin zymography and stromal invasion experiment, respectively. RESULTS: The data showed, the degree of inhibition in migration and invasion of chondrosarcoma cells closely was related to the alendronate sodium treated dose and time. In addition, detected with gelatin zymography and RT-PCR, alendronate sodium significantly reduced mRNA levels and enzyme matrix metalloproteinase activity in a concentration related manner. CONCLUSION: Alendronate sodium can reduce the matrix metallo- proteinases in transcription and translation level, and inhibit the invasion of chondrosarcoma cells. Therefore, alendronate sodium, an adjuvant therapy agent, can be used as a systemic treatment for chondrosarcoma and other malignant tumour.

Key words: alendronate sodium, bisphosphonate, chondrosarcoma

CLC Number:

R965.2

LE Fang-hua, LOU Xing-fa, FANG Qin-hua. Study of adjuvant treatment of alendronate sodium in human chondrosarcoma cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 410-414.

References

[1] 邰艳红, 耿明. 骨外黏液样软骨肉瘤研究进展[J]. 中华肿瘤防治杂志, 2007, 14(6): 463-466.
[2] Yuan J, Dutton CM, Scully SP. RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion[J]. J Orthop Res 2005, 23(6): 1467-1474.
[3] Kawata R, Shimada T, Maruyama S, et al. Enhanced production of matrix metalloproteinase-2 in human head and neck carcinomas is correlated with lymph node metastasis[J]. Acta Otolaryngol, 2002, 122(1): 101-106.
[4] 高峰, 刘淑霞, 郝军,等. 软骨肉瘤中MMP-1及TIMP-1的表达及意义[J]. 临床与实验病理学杂志, J Clin Exp Pathol, 2011, 27(10): 1074-1076.
[5] Pei Y, Harvey A, Yu XP, et al. Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects[J]. Osteoarthritis Cartilage, 2006, 14(8): 749-758.
[6] Berend KR, Toth AP, Harrelson JM, et al. Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma [J]. J Bone Joint Surg Am, 1998, 80(1): 11-17.
[7] Yang SF, Hsieh YS, Lin CL, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients[J]. Clin Chim Acta, 2005, 354(1/2): 91-99.
[8] Yoon SO, Park SJ, Yun CH, et al. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis [J]. J Biochem Mol Biol, 2003, 36(1): 128-137.
[9] Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells[J]. Biochim Biophys Acta, 2005, 1755(1): 37-69.
[10] Clezardin P. Anti-tumour activity of zoledronic acid[J]. Cancer Treat Rev, 2005, 31(Suppl 3): 1-8.
[11] Muller S, Migianu E, Lecouvey M, et al. Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro [J]. Anticancer Res, 2005, 25(4): 2655-2660.
[12] Cheng YY, Huang L, Lee KM, et al. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines[J]. Pediatr Blood Cancer, 2004, 42(5): 410-415.
[13] Forsea AM, Muller C, Riebeling C, et al. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells[J]. Br J Cancer, 2004, 91(4): 803-810.
[14] Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines[J]. Br J Cancer, 2000, 82(8): 1459-1468.
[15] Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates[J]. Cancer, 2000, 88(12 Suppl): 2961-2978.
[16] 郭郡浩, 姚茹冰, 赵智明, 等. 利塞膦酸钠胶囊治疗绝经后骨质疏松症疗效的影响因素分析[J]. 中国临床药理学与治疗学, 2009, 14(7): 818-822.
[17] 林秀峰, 俞惠新, 谭成, 等. 双膦酸盐对肺癌细胞增殖的影响[J]. 中国肺癌杂志, 2005, 8(6): 510-512.
[18] Clezardin P. The antitumor potential of bisphosphonates[J]. Semin Oncol, 2002, 29(6 Suppl 21): 33-42.
[19] Green JR. Antitumor effects of bisphosphonates[J]. Cancer, 2003, 97(3 Suppl): 840-847.
[20] Heymann D, Ory B, Gouin F, et al. Bisphosphonates: new therapeutic agents for the treatment of bone tumors[J]. Trends Mol Med, 2004, 10(7): 337-343.

Study of adjuvant treatment of alendronate sodium in human chondrosarcoma cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles

Metrics

Comments